Martine Rothblatt, United Therapeutics CEO, sells $5.2m in shares

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (NASDAQ:UTHR), recently sold company shares valued at approximately $5.23 million. The transactions, which occurred on October 12, 2026, were part of a pre-arranged 10b5-1 trading plan. The sale comes as UTHR stock trades at $543.40, up 25% over the past year, though InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value.

Ms. Rothblatt disposed of a total of 9,500 shares of common stock across multiple trades. The shares were sold at prices ranging from $547.54 to $554.71. The total value received from these sales amounted to $5,231,666.

Prior to these sales, Ms. Rothblatt acquired 9,500 shares of common stock through the exercise of stock options at an exercise price of $117.76 per share. This exercise represented a total value of $1,118,720.

Both the option exercise and subsequent sale were executed under a Rule 10b5-1 trading plan that Ms. Rothblatt adopted on November 7, 2025. This plan is set to continue until either 1,734,410 stock options, expiring on March 15, 2027, are exercised, or until December 31, 2026, whichever comes first. The stock options exercised on October 12, 2026, vested in equal one-third installments on March 15, 2021, 2022, and 2023. Following these transactions, Ms. Rothblatt’s beneficial ownership of common stock includes shares held indirectly through various family trusts. For deeper insights into UTHR’s financial health and comprehensive analysis, investors can access the company’s Pro Research Report, available exclusively on InvestingPro.

In other recent news, United Therapeutics reported its second-quarter 2026 earnings, revealing an earnings per share of $7.27, which surpassed Wall Street’s estimate of $7.09. However, the company’s revenue of $783.3 million did not meet the forecasted $807.05 million, marking a revenue miss of approximately 2.9%. Following these results, BofA Securities adjusted its price target for United Therapeutics, lowering it from $613 to $559, while maintaining a Neutral rating, citing the revenue shortfall and changes in Tyvaso sales guidance. Additionally, United Therapeutics recently secured a favorable outcome in a patent case concerning its Tyvaso franchise, which led Cantor Fitzgerald to reiterate its Overweight rating with a $700 price target. BTIG also upgraded its stock rating for United Therapeutics from Neutral to Buy, setting a new price target of $728, attributing the upgrade to the positive patent ruling’s impact on competitors like Yutrepia. Meanwhile, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating and a price target of $321, noting a declining base business and a higher price-to-earnings ratio compared to its historical median. These developments reflect the mixed outlook from analysts and the market’s response to the company’s recent performance and legal victories.